Teva Announces Publication of New Clinician Scale in Journal of Clinical Psychiatry to Assess the Impact of Tardive Dyskinesia on Patients’ Lives
23 Février 2023 - 2:00PM
Business Wire
- First-of-its-kind scale provides a standardized method for
healthcare providers to measure tardive dyskinesia (TD) burden
beyond movement severity
- Developed in partnership with the TD community, this scale
incorporates insights from patients, caregivers and
providers
- Offers the potential to more accurately monitor disease
progression and help improve overall TD treatment and care
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical
Industries Ltd. (NYSE and TASE: TEVA), today announced the print
publication of the IMPACT-TD Scale, an easy-to-use, standardized
and clinician-rated assessment. The scale, developed by a consensus
panel, will assist healthcare providers in determining the impact
of tardive dyskinesia (TD) on different aspects of a patient’s
daily functioning.
IMPACT-TD categorizes the consequences of TD symptoms into
multiple functional domains: social, psychological/psychiatric,
physical and vocational/educational/recreational. The scale was
developed to collect insights from not only patients but also
family members, caregivers and providers, to help foster more
productive dialogue and provide the most comprehensive
understanding of the impact of TD.
“Three out of four people who have TD say it severely impacts
how they function, feel and interact with others. Yet, current
clinical evaluation practices focus mainly on the severity of TD
movements,” said Richard Jackson, MD, Assistant Clinical Adjunct
Professor, University of Michigan School of Medicine Department of
Psychiatry and lead author of the consensus statement. “Access to a
standardized scale may provide a more thorough picture of a
patient’s condition, helping to accurately monitor disease
progression and potentially improve overall TD management and
care.”
TD is a highly debilitating, chronic movement disorder that
affects one in four people who take certain mental health
treatments and is characterized by uncontrollable, abnormal and
repetitive movements of the face, torso and/or other body parts. In
the U.S., more than 780,000 people are living with TD but less than
15 percent have been formally diagnosed.
“Partnering with clinicians to evolve the treatment of TD
remains a top priority for us,” said Eric Hughes, MD, PhD,
Executive Vice President of R&D and Chief Medical Officer at
Teva. “That’s why, along with our recent accomplishment of bringing
a new treatment option to the community, we continue to support
initiatives like this to advance care beyond therapies alone.”
The IMPACT-TD Scale consensus statement was published online in
the Journal of Clinical Psychiatry in November 2022, and is out in
print today. The consensus panel and published statement were
sponsored by an independent medical grant from Teva.
About Teva
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has
been developing and producing medicines to improve people’s lives
for more than a century. We are a global leader in generic and
innovative medicines with a portfolio consisting of over 3,500
products in nearly every therapeutic area. Around 200 million
people around the world take a Teva medicine every day, and are
served by one of the largest and most complex supply chains in the
pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of innovative medicines and
biopharmaceutical products. Learn more at www.tevapharm.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, which are based on management’s current beliefs and
expectations and are subject to substantial risks and
uncertainties, both known and unknown, that could cause our future
results, performance or achievements to differ significantly from
that expressed or implied by such forward-looking statements. You
can identify these forward-looking statements by the use of words
such as “should,” “expect,” “anticipate,” “estimate,” “target,”
“may,” “project,” “guidance,” “intend,” “plan,” “believe” and other
words and terms of similar meaning and expression in connection
with any discussion of future operating or financial performance.
Important factors that could cause or contribute to such
differences include risks relating to the development and
commercial success of AUSTEDO®; our ability to successfully compete
in the marketplace, including our ability to develop and
commercialize biopharmaceutical products, competition for our
innovative medicines, including AUSTEDO, AJOVY® and COPAXONE®, our
ability to achieve expected results from investments in our product
pipeline, our ability to develop and commercialize additional
pharmaceutical products, and the effectiveness of our patents and
other measures to protect our intellectual property rights; our
substantial indebtedness; our business and operations in general,
including, the impact of global economic conditions and other
macroeconomic developments and the governmental and societal
responses thereto, and costs and delays resulting from the
extensive pharmaceutical regulation to which we are subject;
compliance, regulatory and litigation matters, including failure to
comply with complex legal and regulatory environments; other
financial and economic risks; and other factors discussed in our
Annual Report on Form 10-K for the year ended December 31, 2022,
including in the section captioned “Risk Factors.” Forward-looking
statements speak only as of the date on which they are made, and we
assume no obligation to update or revise any forward-looking
statements or other information contained herein, whether as a
result of new information, future events or otherwise. You are
cautioned not to put undue reliance on these forward-looking
statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230223005296/en/
IR United States Ran Meir (267) 468-4475
Yael Ashman 972 (3) 914-8262
PR United States Doris Yiu (973) 265-3752
Yonatan Beker (973) 917-0851
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Teva Pharmaceutical Indu... (NYSE:TEVA)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024